Business
Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial
Jupiter, Florida, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical
About this update from Jupiter Neurosciences, Inc.
[{"type":"text","content":"Jupiter, Florida, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced a strategic partnership with Zina Biopharmaceuticals, LLC (\"Zina\") to support all aspects of Jupiter’s upcoming Phase 2a clinical trial for Parkinson’s disease. Under the terms of the agreement, Zina will provide comprehensive services related to the execution of the exploratory Phase 2a trial evaluating JOTROL™, Jupiter’s patented resveratrol-based therapeutic platform. The primary objective of the trial will be to evaluate the safety and tolerability of JOTROL in patients with Parkinson’s, with secondary and exploratory endpoints to assess pharmacokinetics/pharmacodynamics (PK/PD) of the drug. JOTROL’s innovative micellar formulation overcomes the historical limitations of resveratrol by achieving significantly enhanced bioavailability while minimizing gastrointestinal side effects. Preclinical studies have demonstrated JOTROL’s potential in mitigating key biomarkers associated with neurodegeneration, supporting its potential application in Parkinson’s disease and other central nervous system (CNS) disorders. “This partnership with Zina marks a significant milestone for Jupiter as we advance JOTROL into Phase 2 clinical development for Parkinson’s,” said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. “Zina’s extensive expertise in trial execution, as well as regulatory, clinical and scientific strategy, will be instrumental in accelerating our development timeline and positioning us for future pivotal studies.” Under the agreement, Zina will assist with clinical trial protocol design, including pharmacokinetics and biomarkers, regulatory strategy, and trial site selection to facilitate a smooth trial execution and future clinical progression. Parkinson’s disease affects over 10 million people worldwide, with no disease-modifying treatments currently available. The global Parkinson’s therapeutics market is projected to exceed $14 billion by 2030, highlighting the urgent need for novel interventions. Jupiter Neurosciences remains committed to leveraging JOTROL’s unique pharmacological advantages to address this significant unmet medical need. Jupiter is actively exploring additio...